Pharma Works – Tenil Tue, 05 Jul 2022 03:09:39 +0000 en-US hourly 1 Pharma Works – Tenil 32 32 Chronic Obstructive Pulmonary Disease Market Size, Scope and Forecast Tue, 05 Jul 2022 03:09:39 +0000

New Jersey, United States – The Chronic Obstructive Pulmonary Disease Market The research report aims to provide a quick overview of the overall industry performance and important new trends. Important information, as well as conclusions, latest key drivers and constraints, are also described here. A wide range of quantitative and qualitative techniques are used by market analysts, including in-depth interviews, ethnography, customer surveys, and secondary data analysis. It becomes easy for major players to collect important data regarding key organizations along with information such as customer behavior, market size, competition and market needs. By referring to this Chronic Obstructive Pulmonary Disease Market research report, it becomes easy for key players to make evidence-based decisions.

This Chronic Obstructive Pulmonary Disease Market research report adds the potential to impact its readers and users as market growth rate is affected by innovative products, increase in demand for the product, the richness in raw materials, the increase in disposable income and the modification of consumer technologies. It also covers the effect of COVID-19 virus on market growth and development. Market participants can briefly study the report before investing in the market and expect higher returns. According to the report, the market scenario continues to fluctuate based on many factors.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @

Key Players Mentioned in the Chronic Obstructive Pulmonary Disease Market Research Report:

AstraZeneca, Astellas Pharma Inc., Abbott Laboratories, GlaxoSmithKline plc., Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Circassia Pharmaceuticals, Pfizer and Almirall.

Several industries are interested in determining what the customers really want and the Chronic Obstructive Pulmonary Disease market report helps in this regard by carrying out detailed market research. Before bringing a new product to market, every business owner wants to know the demand for the product, and this market research report is the best guide for them. It further helps in meeting business requirements by covering all the latest advances in the market. The Chronic Obstructive Pulmonary Disease Market report is the best way to keep a close eye on the activities of leading competitors as well as their strategies for expanding their business. It further conducts in-depth analysis for the 2022-2028 assessment period to provide more business opportunities for business owners.

Chronic Obstructive Pulmonary Disease Market Segmentation:

Chronic Obstructive Pulmonary Disease Market, By Type

• Chronic bronchitis
• Emphysema

Chronic Obstructive Pulmonary Disease Market, By Treatment Type

• Oxygen therapy
• Lung transplant
Drug therapy
• Operation
• Others

Chronic Obstructive Pulmonary Disease Market, By End User

• Hospitals and Clinics
• Home care settings
• Others

Inquire for a discount on this Premium Report @

Scope of Chronic Obstructive Pulmonary Disease Market Report

UNITY Value (million USD/billion)
SECTORS COVERED Types, applications, end users, and more.
REPORT COVER Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst business days) with purchase. Added or changed country, region and segment scope.

Answers to key questions in the report:

1. Who are the top five players in the Chronic Obstructive Pulmonary Disease market?

2. How will the Chronic Obstructive Pulmonary Disease market develop over the next five years?

3. Which product and application will occupy the lion’s share of the Chronic Obstructive Pulmonary Disease market?

4. What are the drivers and restraints of the Chronic Obstructive Pulmonary Disease Market?

5. Which regional market will show the strongest growth?

6. What will be the CAGR and size of the Chronic Obstructive Pulmonary Disease market throughout the forecast period?

For more information or query or customization before buying, visit @

Visualize the Chronic Obstructive Pulmonary Disease Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI platform for market narrative storytelling. VMI offers in-depth forecast trends and accurate insights on over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a global overview and competitive landscape with respect to region, country and segment, as well as key players in your market. Present your market report and results with an integrated presentation function that saves you more than 70% of your time and resources for presentations to investors, sales and marketing, R&D and product development. products. VMI enables data delivery in Excel and interactive PDF formats with over 15+ key market indicators for your market.

Visualize the chronic obstructive pulmonary disease market using VMI@

About Us: Verified Market Research®

Verified Market Research® is a leading global research and advisory firm that for over 10 years has provided advanced analytical research solutions, personalized advice and in-depth data analysis to individuals and businesses seeking accurate research, reliable and up to date. technical data and advice. We provide insight into strategic and growth analytics, the data needed to achieve business goals, and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable insights. The industries we cover span a wide spectrum, including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and the gas. Etc.

At Verified Market Research, we help in understanding holistic market indicator factors and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and review data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

Having served over 5000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for companies around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US Toll Free: +1 (800)-782-1768



Incentive scheme linked to research in work for the pharmaceutical industry Sun, 03 Jul 2022 07:58:00 +0000

The details of the RLI scheme are not yet specified, but to be eligible for the incentives, companies may be asked to invest at least 15% of their turnover in R&D.

pharmaceutical companies | biocon | Coronavirus vaccine

Sohini Das |

The Center may announce a Research Linked Incentive (RLI) program for the pharmaceutical industry to increase contribution to research and development (R&D) and move up the innovation value chain, it said. sources close to the development.



What do you get on Business Standard Premium?


Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

First published: Sun 03 Jul 2022. 13:28 IST

Pharmaceutical patents under fire from the federal circuit, according to the petitions Fri, 01 Jul 2022 10:06:48 +0000

Growing frustration among pharmaceutical patentees over the Federal Circuit’s tightening of patent law provisions that require inventors to describe in detail what they have created has led to multiple Supreme Court petitions seeking to put the country’s leading patent appeals court.

Over the past decade, the United States Court of Appeals for the Federal Circuit has adopted higher standards to meet the requirements of the law that patents provide a clear written description and enable others to understand the invention. Three separate petitions for review are now asking the High Court to look at tests that have evolved from statutory language that set benchmarks for how patent holders fully disclose their inventions – the tests say lawyers have created a particularly heavy burden on the life sciences industry.

Recent decisions invalidating pharmaceutical patents held by Bristol-Myers Squibb Co. Juno Therapeutic, Biogen International GmbHand Amgen Inc. show how difficult it is for drugmakers and biotech companies to meet federal circuit standards, the attorneys said.

“I hope the Supreme Court can make a correction to the course we are currently on,” said Hailey Bureau, patent attorney at Birch, Stewart, Kolasch & Birch LLP. “The court has been going down this road for the past decade, but now it looks like the last three very recent decisions have come to a head in the last year.”

Describe an invention

Section 112(a) of the Patent Act requires that “patent claims must state what an inventor or co-inventor considers to be the invention”. From there, more specific provisions require a “written description of the invention, and of the manner and process of making and using it, in full, clear, concise and accurate terms enabling” a skilled person in the art of making and using the invention. The Federal Circuit treats this language as two separate issues, the lawyers say: a written description requirement and a clearance standard.

Both prongs of Section 112 were improperly enforced by the federal circuit, drugmakers claim, which they say led to the invalidation of patents for breakthrough cancer treatments and a blockbuster cancer drug. multiple sclerosis.

The Complete Federal Circuit held in 2010 Ariad vs. Eli Lilly ruling that the written description requirement is distinct from the authorization. Testing, however, is two sides of the same coin, Bureau said.

“They are very intertwined. If you can show clearance, you should have a written description,” Bureau said. “The court decided on its own initiative to split them into two requirements of written description and enabling, but whether or not that was Congress’s intention, it probably isn’t.”

full ownership

The Biogen and Juno Therapeutics petitions both address whether the Federal Circuit went too far in what is necessary to show that an inventor has full possession of the invention, a way of showing that there is an adequate written description.

“The question is not only how do we as claimants show possession, [but] how do we show that we have enough possession? Office said. “Based on some goalposts the Federal Circuit has set, it appears to be invisible that no one else can see except the court.”

Biogen’s patent for the drug MS Gilenya fell because the patent failed to show the invention was “effective”, prompting dissent from several judges, who said the ruling would cloud case law. Simply listing ingredients and methods once, without proving efficacy, should suffice, Judge Alan D. Lourie wrote in a dissent from the Full Federal Circuit’s decision not to rehear the case.

“If the written description standard is now going to require proof of efficacy in a patent application, it also creates a problem for pharmaceutical companies to decide when to file for patent protection,” said patent attorney Emer Simic. at Neal, Gerber & Eisenberg. LLP in Chicago. “This creates significant concern for pharmaceutical companies researching drugs for the treatment of various conditions.”

Juno’s patent failed to show how specific antibodies would work in his technique, in which T cells from a person’s own immune system are modified to attack cancer cells, the Federal Circuit ruled, reversing a jury verdict of $1.2 billion. While Juno’s patent offered some examples of antibodies, the Federal Circuit did not find it sufficient.

“It really places a very heavy burden on the plaintiff — an incredible, perhaps even untenable burden,” Bureau said. “We have found ourselves in a situation that is not ideal for patent applicants or patentees in these cases.”

Juno said the Federal Circuit went beyond the law and “erases vast swathes of patents.” Biogen warned that the decision revoking its patent would have a “chilling effect on innovation”.

Bigoen may be in the best position to win a Supreme Court grant, Simic said, pointing to the split between judges and the High Court’s denial of other petitions involving gender claims – patents that cover a group of related substances, rather than a specific compound – such as those at issue in the Juno and Amgen petitions.

“Impossible Burden”

Last year, the Federal Circuit found that Amgen’s patents on its cholesterol drug Repatha, which covered hundreds of distinct antibodies, were too broad to be valid, failing the clearance requirement .

The ruling created a new hurdle for gender claims, Amgen argued in its Supreme Court petition, saying the Federal Circuit expanded the test to require the patent to allow a qualified expert to identify and make cumulatively almost all possible variants of the invention without substantial. time and effort.

Teaching every gender assertion which works and which doesn’t would be an impossible burden, said Stanford University law professor Mark Lemley.

“This is going to make it difficult for almost everyone in the pharma and bio space to get a gender claim in the future,” Lemley said. “I don’t think the lawyers and the pharmaceutical companies who are writing the patents have somehow fully focused on the fact that, you know, when these things come to court years later, they’re not going to survive.”

If the Juno and Amgen decisions are left in place by the Supreme Court, no attempt to define an antibody will be enough to satisfy the Federal Circuit, said University of Illinois law professor Jacob S. Sherkow, who with Lemley wrote an article about antibody patents falling in court of appeal.

“Most importantly, it leaves us in a world where almost all antibody patents covering any major product, any treatment, any diagnostics – any patent covering antibodies – will all be subject to ‘be invalidated under that same standard,’ Sherkow said. said.

“It would only erase billions of dollars worth of intellectual property.”

11th Annual SPDS International Conference, Disso India 2022 Online Inaugurated by Dr. Rajeev Raghuvanshi Wed, 29 Jun 2022 01:30:00 +0000

Disso India 2022

MUMBAI, MAHARASHTRA, INDIA, June 29, 2022 / — The Society for Pharmaceutical Dissolution Sciences (SPDS), organized the 11th Annual International Conference of SPDS – Disso India 2022 – from June 23-25, 2022 in collaboration with the American Association of Pharmaceutical Scientists (AAPS). Held annually, this flagship conference of the Society for Pharmaceutical Dissolution Science (SPDS) brought together pharmaceutical R&D, QA and QC professionals as well as Indian and overseas scholars, involving speakers from the United States, Europe and Asia. The international conference took place online from June 23 to 25, 2022 (3:00 p.m. to 8:00 p.m. IST)

‘Advances in Dissolution Science’ was the theme of the conference. The Society for Pharmaceutical Dissolution Science (SPDS) has gained international recognition and acceptance in a short time.

Dr. Rajeev Raghuvanshi, Scientific Director-Secretary, Indian Pharmacopoeia Commission, opened the conference and delivered his keynote address. Dr. Rubina Bose, Deputy Comptroller of Medicines (India) was the guest of honor at the conference.

The 2nd Edition of Pharmaceutical Dissolution Science Desk Book was also published by Chief Guest Dr. Rajeev Raghuvanshi. Dr Ramaswamy has announced a special pre-print offer for Disso India delegates who can book their copy directly from

The Disso India 2022 Scientific Abstract Book has been officially released and will be made available on the SPDS website.

Disso India- 2022 Online organized around 20 lectures over a period of 3 days by eminent professionals working in the pharmaceutical industry across the globe as well as academia. More than two thousand professionals from pharmaceutical R&D, QA, QC and universities around the world attended this event on the first day.

The scientific sessions were programmed and executed under the chairmanship of Professor Arvind Bansal, Professor and Head of Department of Pharmacy, NIPER, SAS Nagar, and Co-Chairman-Dr. Vinod. P. Shah, ex-USFDA and pharmaceutical consultant, United States. A galaxy of prominent speakers enlightened attendees on current dissolution-centric technologies and science.

Teacher. Arvind Bansal (Dean, NIPER, SAS Nagar, India), Dr. Indu Bhushan (Steers Engineering), Dr. Rajashri Shinde (ABITEC), Prof. Padma Devarajan, (Institute of Chemical Technology, India), Prof. Dianne Burgess, (UCONN School of Pharmacy, Connecticut), Dr Jean Cardot, (University of Auvergne, France), Dr Vinod P. Shah (Pharmaceutical Consultant, USA), Dr Deanna Mudie (R&D, Lonza Inc, USA), Dr . Varsha Pradhan, (ICT Mumbai), Samir Haddouchi (SPS Pharma Services, Orléans, France), Dr Deirdre D’Arcy (Trinity College, Ireland), Kempf Jurgen (SOTAX AG, Switzerland), Dr Ajay Saxena (BMS, USA ), Dr Xujin Lu (BMS, USA), Sandeep Kulkarni (Image Provision Technology Pvt. Ltd. India), Holger Herman (SOTAX AG, Switzerland), Vijay Kshirsagar (TRAC Pharma Consulting, Mumbai), Dr Anant Ketkar (Scientific Lead-India, Simulation Plus, Inc.) were among the conferences that were part of Disso India 2022 Online.

The event was supported by companies like SOTAX and ACG who were Platinum partners of the event along with BASF, Electrolab, Steer Engineering, Abitec corp, Image Provision Technology and Inveniolife.

A registered NGO, Society for Pharmaceutical Dissolution Science (SPDS) was established on July 16, 2012 in Mumbai with the aim of promoting scientific and technological development in the field of dissolution science among pharmaceutical professionals, academics, students, regulatory bodies, etc. SPDS is the only professional body dedicated to Dissolution and its application in the world. SPDS envisions being one of the most important organizations focusing on dissolution science in the pharmaceutical industry and academia.

SPDS has proudly partnered with the American Association of Pharmaceutical Scientists (AAPS) for this year’s Disso India 2022 event. Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional scientific organization of approximately 7,000 individual members and more than 10,000 active stakeholders employed in academia, industry, government and other research institutes related to pharmaceutical sciences all over the world. The mission of AAPS is “to advance the ability of pharmaceutical scientists to develop products and therapies that improve global health.” It operates on five core values ​​- Learning, Innovation, Service, Inclusiveness and Integrity.

Dr Prakash Bhosale
+91 8097027355
write to us here
Visit us on social media:

Size, Cost Structures, Growth Rate – Designer Women Sat, 25 Jun 2022 10:27:39 +0000

According to Hormonal Contraception Market Report 2030, examines various factors driving or restraining the Hormonal Contraception Market, which will help the future market to expand with a promising CAGR. Hormonal Contraception Market Research Reports offers an extensive collection of reports on different markets covering crucial details. The Hormonal Contraception report studies the competitive environment of the Hormonal Contraception market is based on company profiles and their efforts on increasing product value and production.

Hormonal Contraception Market the research study involved the extensive use of primary and secondary data sources. The Hormonal Contraception research process involved the study of various factors affecting the industry including market environment, competitive landscape, historical data, current Hormonal Contraception market trends, technological innovation, upcoming technologies and technical advancements in the related industry, and market risks, opportunities, market barriers and challenges.

Get a Free Sample Report @ Hormonal Contraception

The Hormonal Contraception Final Report will add the analysis of the impact of Covid-19 in this Hormonal Contraception Market Report.

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the world Hormonal Contraception Market is included in this report on hormonal contraception. The influence of the novel coronavirus pandemic on the growth of the Hormonal Contraception market is analyzed and described in the report..

Some of the competing companies in the hormonal contraception market are

Merck & Co., Inc., Harleston, SC., Bayer Pharma AG, Afaxys, Inc., Teva Pharmaceutical Industries Limited, Agile Therapeutics Inc.,

Most Important Types of Hormonal Contraception Products Covered in this Report are: Oral Pill Skin Patch Intrauterine Device (IUD) Implantation Most widely used downstream areas of Hormonal Contraception Market Covered in this report are: Hospitals Home Care Services Centers for gynecologyClinicsOutpatient surgical centers

The Hormonal Contraception report examines different business approaches and frameworks that pave the way for business success. The Hormonal Contraception report has used expert techniques to analyze the Hormonal Contraception market; it also offers a review of the global hormonal contraception market. To make the report more powerful and easy to understand, it consists of infographics and diagrams. Also, it has different development policies and plans which are presented in summary. It analyzes technical barriers, other issues, and cost-effectiveness affecting the Hormonal Contraception market.

Global Hormonal Contraception Market The 2021 Research Report contains in-depth Case Studies on the various countries involved in the Hormonal Contraception market. The Hormonal Contraception report is segmented according to usage, if any, and the report offers all this information for all major countries and associations. It offers an analysis of technical barriers, other issues, and profitability affecting the Hormonal Contraception market. Important contents analyzed and discussed in the Hormonal Contraception report include market size, operations status and Hormonal Contraception market current and future development trends, market segments, business development and consumption trends. Moreover, the report includes the list of leading companies/competitors and their competition data which helps the user to determine their current position in the market and take corrective measures to maintain or increase their shares.

What questions does the Hormonal Contraception market report answer on the regional scope of the industry

The Hormonal Contraception report claims to split the regional scope of the Hormonal Contraception market into North America, Europe, Asia-Pacific, South America and Middle East & Africa. Which of these regions has been touted to amass the largest market share over the projected duration

  • What the sales numbers look like now What the sales scenario looks like in the future
  • Considering the current scenario of hormonal contraception, how much revenue will each region reach by the end of the forecast period
  • What is the hormonal contraception market share that each of these regions has accumulated currently
  • What is the growth rate of hormonal contraception that each topography will represent on the projected timeline

Buy a copy of this Hormonal Contraception Report @

The scope of the report on hormonal contraception:

The report segments the global hormonal contraception market on the basis of application, type, service, technology, and region. Each chapter of the Hormonal Contraception report under this segmentation allows the readers to grasp the details of the Hormonal Contraception Market. A magnified look at the segment-based analysis aims to give readers a deeper insight into the opportunities and threats in the hormonal contraception market. It also discusses political scenarios that are expected to impact the market both small and large. The Hormonal Contraception Global Hormonal Contraception Market report examines changing regulatory scenarios to make accurate projections on potential investments. It also assesses the risk to new entrants and the intensity of competitive rivalry.

Reasons to buy this report

  • Highlights key business priorities to help hormonal birth control companies realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Hormonal Contraception Market, thereby allowing players to develop effective long term strategies.
  • Develop/modify business expansion plans utilizing substantial growth offering in both developed and emerging hormonal contraceptive markets.
  • Discuss in depth the global hormonal contraception market trends and outlook associated with the factors driving the market, as well as those restraining it.
  • Improve the decision-making process by understanding the strategies that drive business interest in components, type, and end users.

About Us is a global provider of market research and advisory services specializing in offering a wide range of business solutions to its clients, including market research reports, primary and secondary research, demand forecasting services, focus group analytics and other services. We understand how important data is in today’s competitive environment and so we have partnered with industry leading research providers who are constantly working to meet the ever-increasing demand for research reports. market throughout the year.

Contact us:

Carl Allison (Business Development Manager)

Tiensestraat 32/0302,3000 Leuven, Belgium.

Market reports

phone: +44 141 628 5998



My day: Grainne Hughes, Almac Pharma Services Thu, 23 Jun 2022 15:10:00 +0000

At 8am, I’m in my car and already halfway from the office to Almac’s headquarters in Craigavon. I am married with three sons, my husband is a teacher and we are also part-time farmers, so our mornings are extremely busy. I also make sure to schedule time to exercise every morning of the week – I find it invigorating and allows me to focus so I can perform at my best throughout the day.

I usually arrive at the office around 8:30 am and immediately prepare for the day ahead. I’m an avid list-maker and no two days are ever the same, so I check my notes from the night before and review my calendar for scheduled meetings and calls. Then 9am is the start of my meeting schedule, so I like to grab a coffee and get my bottle of water ready for the day ahead.

My individual appointments are scheduled in the morning. As a company, our overriding mission is to advance human health and we are responsible for the packaging and delivery of niche commercial drugs for rare diseases, some of which can change the life of the patient who relies on us. to ensure that the drug is delivered on time and at the highest possible quality. We work with different disciplines and I draw on my background and experience to help teams deliver the best service to our clients.

Over the past three years we have experienced phenomenal growth as we meet increasing demand, which is why recruitment and training is a priority at the moment. In 2021, we announced the recruitment of 1,800 new employees globally, including 1,000 based here in Northern Ireland. This year we recruited interns, creating a pool of potential resources for the future, and they have been a great addition to our teams. I have a degree in biomedical sciences and have evolved into a role that requires a combination of science and a strong focus on business development. Likewise, my team has similar educational paths that work incredibly well.

12 p.m.
I usually join my client services team at this time to ensure that service delivery runs smoothly and discuss any challenges that arise. This gives me the opportunity to discuss clients’ long-term strategic goals, allowing us to assess how we might develop our partnership. I also meet regularly with potential customers to introduce them to Almac and explain how we could meet their needs.

2 p.m.
Another function within my mission is business excellence – as a company, we spend time introducing new ways of working that drive efficiencies and strengthen our overall performance. After lunch, I enjoy spending time with this team reviewing initiatives using benefit analysis and resource assessment processes and discussing potential delivery against our current business priorities.

4 p.m.
At this time of day, I check delivery and revenue performance metrics for our customers and liaise with my sales teams to make sure everything is going according to plan. As a global company, this part of the day is spent meeting with US clients, after which I have the opportunity to download the day and make a list of tasks that I need to follow up on the next morning.

6 p.m.
I try to leave the office at 6 p.m. and once home, my family and I sit down to dinner together and catch up on our respective days. Then it will be a mix of helping with homework and preparing lunches and dinner the next day, giving us a much-needed head start the next morning. Being organized is key to managing all aspects of my busy life. Although there is a lot of work to do, I am passionate about my career and my family and enjoying every moment.

Kestria adds Pender & Howe to its network Tue, 21 Jun 2022 14:53:52 +0000

June 21, 2022 – Kestria, formerly known as IRC Global Executive Search Partners, has expanded its presence in North America with the addition of Toronto-based Pender & Howe Executive Search as a new member firm. “We are delighted to represent Kestria in Canada and the United States, and we are committed to fulfilling the alliance’s mission to provide first-class executive search services wherever you are in the world, through our efforts in Canada and the United States,” said Travis Hann. , managing partner of Pender & Howe. “We are confident that this partnership will be mutually beneficial for many years to come.

“It is exciting for all of us at the Kestria Alliance to welcome our new like-minded colleagues Glenn Lesko, Travis Hann, Céline Chabée and their team,” said Stepan Motejzik, Alliance Director at Kestria. “Their deep expertise of the North American market will greatly enhance our ability to meet client needs and serve as trusted advisors to strengthen businesses in the region and globally.”

Pender & Howe Executive Search is a boutique executive search firm with offices in Toronto, Montreal, New York, Edmonton, Vancouver and San Francisco. The firm has over 30 years of combined experience in leadership consulting and executive search.

Pender & Howe is focused on working with boards and CEOs to identify world-class leaders. It provides leadership solutions that encompass venture capital firms, private equity, new technologies, emerging sectors, as well as board advisory positions. Its clients range from pre-seed startups and VC-backed disruptors to global public companies. His specialties include executive search, CEO search, leadership strategy, succession planning, executive assessment, talent management, executive search, culture transformation, consulting services of administration and digital transformation.

Kestria has partners in over 80 cities across Europe, the Middle East, the Americas, Africa, Asia and Australia. The consortium has completed more than 30,000 assignments for more than 3,000 clients in virtually every industry segment and function, according to the company. Kestria has performed over 40,000 searches for over 4,000 clients, serving everyone from start-ups to major global players.

New Board of Directors

Kestria recently elected a new executive board. The board is made up of the following members: Rania Abdalla, Tom Berray, Michael Kantel, Katerina Meimaroglou and Rohan Carr (IRC Australia), Chair of the IRC Executive Board. Ms. Meimaroglou, Managing Partner of IRC Greece (MEIHUNT, Enterprise Talent Management), was elected as a new IRC Board Member.

Kestria strives to embrace the flexibility of entrepreneurs and the diversity of a global player. The organization is present in more than 45 countries on six continents. More than 50% of its partner companies are run by women. IRC consultants speak 41 languages ​​and represent more than 50 nationalities. “We are delighted to have Katerina join and strengthen our already talented Board of Directors,” said Mr. Carr, Chairman of Kestria. “She will bring a fresh and unique perspective and we look forward to her contribution.”

Ms. Meimaroglou focuses on senior executive search, particularly in the consumer packaged goods, pharmaceutical and retail sectors. Before founding her own company, she was a partner of Cornerstone International Group. She brings corporate experience in human resources management from multinational organizations such as Coca-Cola Co., where she worked for almost six years in roles of regional human resources and marketing manager in Greece, Cyprus and Malta. Prior to that, she worked for British Petroleum as an HR Advisor.

Contributed by Scott A. Scanlon, Editor; Dale M. Zupsansky, editor; and Stephen Sawicki, Editor – Hunt Scanlon Media

The Movie’s Biggest Changes From The Book Explained Sun, 19 Jun 2022 21:10:00 +0000

Warning: Spoilers for spider head below.

by Netflix spider head changes important details of “Escape from Spiderhead”, the short story by George Saunder on which it is based. A number of these changes are unsurprisingly additions, clearly inserted in an effort to expand under 40 pages into a feature film. However, some of the changes made to spider head completely contradict the events that occur in the source material.

spider head and Escape from Spiderhead both focus on Jeff (Miles Teller) as he is forced to participate in drug trials run by Steve Abnesti (Chris Hemsworth) at a specialized correctional facility. These trials grow increasingly sinister, ranging from the relatively innocuous eloquence of Verbaluce to the suicidal Darkenfloxx. On page and on screen, the story ends with Jeff escaping from the facility, but in completely different settings.


Related: Everything We Know About Netflix’s Spiderhead

While the changes aren’t necessarily bad, Netflix spider head, which was the occasion to buy back Netflix after red notice, seems to ignore some of the central themes of Saunder’s “Escape from Spiderhead.” These include character additions, focus changes, and an unexpected and hopeful ending. Here are the biggest changes between Saunders’ story and the Netflix adaptation.

Rachel was Darkenfloxxed as well as Heather

Chris Hemsworth in Spiderhead movie trailer

spider headThe first change in tone occurs when Steve Darkenfloxxes Heather, which causes her to commit suicide. It plays out the same way in the short story. However, while Heather’s death is more gruesome in the film, one twisted plot detail is omitted. In the name of scientific consistency, Book-Steve also provides Darkenfloxx Rachel, the other woman with whom Jeff was chemically enticed to have sex. This creates the final conflict in the short story, but as spider head went in another direction, this cut makes sense.

There was no focus on the outside world until the end of the story

spiderhead where was it filmed

spider head, which isn’t the only Netflix movie of summer 2022, includes plenty of panoramic shots of the beautiful world outside. In Saunders’ story, however, the reader is never included in what lies beyond the facility until Jeff escapes at the end. Although it’s a subtle difference, the wider cinematic focus helps organize the getaway during spider headis the highlight. This setup is not needed in the story because it ends differently.

Lizzy didn’t exist in the story

Cast and Character Guide - Lizzy and Jeff in Spiderhead

Although it has a central role in spider head, the character of Lizzy was not in the original short story at all. It has a clear function, however, which justifies its inclusion in the film. One of Abnesti’s essays is about the making of love. Under the influence of ED289/290, Jeff falls in love with Heather and Rachel but then feels nothing. Lizzy serves as an unartificial relationship, a comparison of true love to Abnesti’s made-up version.

Related: Did Chris Hemsworth Just Reveal Thor: Love & Thunder Release Date?

The focus on Steve Abnesti was more prominent in the film

Chris Hemsworth as Steve in Spiderhead

Abnesti is an antagonist in “Escape from Spiderhead”, but lacks the depth of Hemsworth’s version in spider head. Chris Hemsworth is a household name, set to reprise his role as Thor in love and thunder, so it would have been pointless to underuse an actor as powerful as him. Additionally, the increased focus on his motivations and background also adds a personal touch to the narrative. Saunders’ story, for example, never reveals Abnesti’s problems with her father. Additionally, there is no clear reason why he is conducting the trials in the story; in order to make Abnesti a more traditional villain, spider head deliberately interrogates his motives in a way Saunders didn’t need to.

Jeff’s criminal past was different

Spiderhead Cast and Character Guide - Jeff

One of the film’s most redundant changes is the reimagining of Jeff’s criminal past. In the story, Jeff is imprisoned for hitting someone with a brick during a fight and is charged with manslaughter. In the spider head movie, directed by Top Gun: Maverick‘s Joseph Kosinski, Jeff has a car accident while under the influence of alcohol, killing both his girlfriend and his friend. Not only are the detailed descriptions of his crime an unnecessary addition to the story, but it’s also unclear why Jeff’s crime couldn’t stay the same.

Prisoners’ backgrounds are sometimes used against them as a reason for Darkenfloxxed. Lizzy, for example, is tortured by herself and Abnesti knowing that she is responsible for her baby’s death. However, this is never properly explored in Jeff’s context, making the move to a more emotional backstory entirely superficial.

The B-6 plot didn’t happen at all

The cast of the movie Spiderhead

In the film’s final act, Jeff discovers the reason behind the drug trials: Abnesti has been trying to perfect B-6, a drug that will control people. In a final showdown that involves Miles Teller resurrecting his Insurgent knife skills, Abnesti explains his master plan to Jeff, which Jeff then foils by alerting the authorities and escaping the facility. B-6 was never part of the short story, but it doesn’t seem out of place in spider head. Saunders keeps many details ambiguous, and while it works in a written format, it would have been unsatisfactory in a visual medium. Adding a larger world domination explanation and scheme helps to better situate the smaller concepts being interrogated throughout. spider head.

Related: Netflix’s Most-Watched Movies Of All Time

[Spoiler’s] Death has not happened

Spiderhead cast and character guide

At the end of spider head, Abnesti’s pursuit of Jeff and Lizzy ends when he crashes his plane into the side of a mountain. Since the entire facility and pharmaceutical experiment belong to him, it is implied that Abnesti’s death marks the end of his twisted drug trials. There are no such suggestions in Saunders’ store. When Jeff escapes, the facility is still working and Abnesti is still alive. The end of the story is a symbolic victory for Jeff as a person, but it is not the societal victory represented in the spider head film.

Jeff didn’t have a happy ending in the story.

Spiderhead's ending explained

In perhaps the biggest change from the source material, Jeff gets a happy ending in Netflix. spider head. In the story, after refusing Darkenfloxx Rachel, he self-administers the drug and flees the facility. Outside, he awaits his own death, finally at peace knowing that he refused to help Abnesti kill anyone.

It probably wouldn’t have worked on screen, especially since a sequel is already in the works. It is not certain that spider head will stand up to the other sci-fi films expected in 2022, but this change shows some willful ignorance on the filmmaker’s part. Big Pharma remains unfazed by the George Saunders story; however, in the film, Jeff is able to dismantle the setup and sail into the sunset with a handsome accomplice on his arm. For a fairly dystopian story, the sweetness of spider headThe ending seems a bit out of place.

Next: Spiderhead Cast & Character Guide

Hustle Breaks Big Adam Sandler Movie Tradition

Are companies doing enough to create inclusive workplaces? Sat, 18 Jun 2022 06:42:00 +0000

Pride Month is celebrated around the world in June to mark the 1969 Stonewall Uprising in Manhattan, a turning point for the gay liberation movement in the United States. As the world has become more aware and accepting of the lesbian, gay, bisexual, transgender and queer (LGBTQ+) community, there is still much to be done to embrace diversity in the workplace.

A recent survey conducted by the Indeed job board found that 71% of respondents believe their organizational diversity and inclusion policies are insufficient.

Almost half of all respondents, 48% to be exact, reported no discrimination at work. However, a few pockets of disagreement remained as 27% of women, 23% of people with disabilities, and 21% of LGBTQ+ employees said discrimination existed, according to the survey shared by Indeed with

Meanwhile, 41% thought the change was gradual and would happen over a horizon of more than a year.

Individual experiences have changed over time and geographies

“You can’t separate who you are as a person from what you do as a professional, so bringing the whole person to work is more productive,” says Pooja Jana (her), queer androgynous and senior data engineer, Wells Fargo India and Philippines.

Jana joined the company in August 2021 and says there is an extensive range of diversity, equity and inclusion (DE&I) programs. She feels safe knowing that she is working where there is zero tolerance for any type of discrimination.

But Ketty Avashia didn’t feel as welcome when she entered the workforce in the late 1990s, when “LGBTQ+” was a big taboo.

“I didn’t feel safe or comfortable coming out publicly. So I tried to navigate that world as a woman,” the 44-year-old transman, who is vice president and head of platform integration at Wells Fargo India and Philippines, told .

“If you were different and did not conform to socially accepted hetero-normative behavior, the chances of being ostracized in the professional and personal world were real,” he said. “This would manifest in a number of ways, including not being placed in customer-facing roles or having your contributions go unrewarded. Early in my career, I faced a situation where customer appreciation for my work as a programmer was not taken into account in my evaluation, and I received less than positive feedback from managers.”

Following this, Avashia moved to the United States in the mid-2000s, where for the first time he was able to express himself without much backlash. “I could embrace my identity for the first time publicly. It was so liberating. He returned a few years later for increased social acceptance at all levels in India as well.

The 2018 Supreme Court decision

September 2018 marked a turning point for LGBTQ+ rights with the historic judgment of the Indian Supreme Court. On September 6, 2018, the Supreme Court decriminalized homosexuality and reversed its own 2013 ruling and partially overturned Section 377, a controversial British-era law that prohibited consensual same-sex relationships. The ban is irrational, indefensible and patently arbitrary, the court noted.

“As a result of this, today’s Gen Z LGBTQ+ tech workforce has witnessed a tectonic shift in how they define themselves and what they expect from their workplace. With higher levels of acceptance today, Gen Z, who will soon make up the majority of the workforce, will only amplify the gains made so far in the DE&I space to create a culture even more inclusive and accepting of the multiple facets of sexuality. orientation and gender identity and expression (SOGIE),” Avashia said.

Has the pandemic brought any changes?

COVID-19 has caused employers to adjust their policies more in favor of the LGBTQ+ community than any other category of employees, according to the Indeed survey. According to the report, 52% of all employers, including 94% of small organizations, say their amended policy gives LGBTQ+ people fairer representation than before.

Seventy percent of employers surveyed believe that the policies they have in place are intact and do not need improvement and only 23% (of which almost a third are small businesses) believe that it is possible to make their DE&I policies more effective.

However, 34% of employees surveyed say the pandemic has not impacted how their organization handles diversity and inclusion. In fact, nearly a third (31%) of employees surveyed said their organization got worse.

BFSI (40%), Automotive (38%), Consumer Durables (35%) and Healthcare & Pharma (33%) sectors, in Bengaluru, Delhi/NCR, Hyderabad, Kolkata and Pune contribute to this sentiment, according to the survey.

Source: Indeed

What should companies do?

Earlier this month, Michael Page, in his report The GreatX, said companies should consider factors such as gender, ethnicity, sexual orientation, education, age and people. disabilities if they want to build a truly diverse and inclusive workforce. .

Most urgently, India needs to address its gender pay gap problem, most companies need to start committing to medium to long term strategies and setting quantifiable targets to ensure that they can advance DE&I.

The report adds that DE&I must start at the top, which means leaders must authentically embrace these values.

Meanwhile, according to the Indeed survey, 77% of employers believe that not prioritizing diversity, inclusion and belonging (DI&B) could hurt their organizational performance. “Even on the job seeker side, Indeed data shows that 73% of employees want to work in organizations that actively promote DI&B initiatives, underscoring the importance of such policies,” said Sashi Kumar, Head of Sales , Indeed India.

Auxilius raises $10 million to help Biopharma manage $150 billion in clinical R&D spending Thu, 16 Jun 2022 13:53:00 +0000

NEW YORK–(BUSINESS WIRE)–Auxilius, the company that simplifies and streamlines the financial management of clinical trials for biotech companies, today announced that it has raised $10 million in Series A funding. The round was led by Renegade Partners, with participation from previous investors Bain Capital Ventures and XYZ Venture Capital, as well as a number of leading angel investors including Andy Palmer (Koa Labs), Chase Gilbert (Built Technologies) and Sam Whitaker (Greenphire ). Roseanne Wincek of Renegade Partners joins the board.

“We have all learned how essential biotechnologies are to the well-being of our communities. And yet they have been largely forgotten by technology, lacking basic financial tools to operate at scale,” said Ross Fubini, Founder and Managing Partner of XYZ Venture Capital. “Auxilius powers essential financial processes and workflows, enabling clinical organizations to focus on science that saves lives.”

Clinical R&D: complex, outsourced and under-managed

Over the past decade, two distinct trends have shaped drug development. First, a noticeable change in where innovation takes place – with more than 80% of registered clinical trials now sponsored by emerging biopharmaceutical companies, up from 55% in 2009. Second, clinical operations are increasingly under -Processed to external vendors, including Clinical Research Organizations (CROs) and a growing set of functional and decentralized service providers. The result is an evolving – and growing – underground industry that emerging biopharmaceutical companies are ill-equipped to manage operationally.

As biotechnologies progress from the laboratory to the clinic to the IPO, drug development is no longer just a matter of science. Nearly a quarter of phase 3 trials fail because of a lack of funding, not because of the safety or effectiveness of the treatment. For clinical trial sponsors managing on a step-by-step basis, operational rigor and expense management are key to extending the company’s track and helping clinical teams achieve clinical results.

“Auxilius empowers biopharmaceutical company finance leaders to make sound business decisions so they can support the important work of their colleagues in clinical development,” said Adam Weisman, co-founder and CEO of Auxilius. “We provide a powerful set of tools that allow companies to exponentially oversee all moving parts – contract terms, change orders, clinical milestones and financial complexities – to keep trial budgets on track.”

“This industry is full of clinical tools and industry-neutral FP&A software, but the bulk of clinical R&D spending has historically been managed manually in spreadsheets,” said Adam Mostafa, CFO of X4 Pharma. “Auxilius was specifically designed for companies like ours to manage clinical complexity, maintain alignment between clinical and financial stakeholders throughout change, and adapt as our organization evolves.”

Built for Biotech: Financial Maturity in a Box

Although the life sciences industry spends $54 billion on software and IT, 90% of all pharmaceutical companies still use spreadsheets and manual data reconciliation for trial accounting, financial management, risk monitoring and reporting. Clinical toolsets (CTMS, EDC) are designed to manage clinical data, not to serve finance managers. Conversely, industry-neutral financial tools, such as accounting software and generic FP&A solutions, were not designed to handle the complexity of clinical R&D. Auxilius bridges this operational gap with a SaaS platform that bundles the process, rigor and efficiency needed to successfully manage a trial into one seamless and intuitive toolset.

The Auxilius SaaS platform unifies disparate clinical, contract, and financial data to enable companies to streamline core FP&A and accounting workflows, hold outsourced vendors accountable in the face of change, and build processes that take supports audit, compliance and reporting requirements. The platform was designed to meet the needs and pace of growth of emerging, scalable, and mature biotech companies – delivering the same financial and operational rigor that would exist at a top 10 pharma company for less than the cost of a full-time employee.

Focus on the big picture

Since its launch late last year, Auxilius has been in the pilot phase with clinical trial sponsors managing 15 preclinical programs through Phase 3, 45 separate vendors and nearly $100 million in capital expenditures. test. The company expects the solution to be deployed to 25 customers by the end of the year.

“The benefit of the Auxilius platform is immediately apparent to biotech companies that now drive the majority of drug research and development,” said Roseanne Wincek, co-founder and CEO of Renegade Partners. “Auxilius could be the difference between bringing a cure for a disease to market and watching it languish in a laboratory.”

“It’s tempting to believe that clinical R&D is inherently unpredictable, and given what’s at stake, that costs don’t matter,” Weisman added. “The reality is that costs matter and play a critical role in determining whether a therapy is ultimately successful. Looking to the future, we are committed to reducing financial risk and disseminating financial intelligence at every stage of the drug development lifecycle. We fundamentally believe that combining financial rigor with cutting-edge science will ultimately make more life-saving therapies available, at affordable costs.

About Auxilius

Auxilius was specifically designed by a team with decades of experience at the intersection of finance and healthcare to meet the unique operational, financial and accounting needs of clinical trials. The company helps biotechs achieve more by augmenting manual clinical business operations and FP&A/accounting processes with intuitive software that scales and works with a company’s existing technology stack. This allows companies conducting clinical trials to control trial costs and clinical vendors, manage financial risk, and optimize expenses in pursuit of trial goals. The company is backed by Bain Capital Ventures, Renegade Partners and XYZ Venture Capital as well as several leading angel investors. To learn more, please visit

About Bain Capital Ventures

Bain Capital Ventures partners with disruptive founders to bring their ideas to market faster. BCV invests from seed to growth in startups that drive transformation across all sectors, from SaaS, infrastructure software and security to fintech, healthcare, commerce and consumer technology. The company has helped launch and market over 395 companies, including Attentive, Digital Currency Group, DocuSign, Flywire,, LinkedIn, Redis Labs, Rent the Runway, SendGrid and SurveyMonkey. BCV has $10 billion in assets under management with offices in San Francisco, New York, Boston and Palo Alto. Follow the firm via LinkedIn and Twitter.

About Renegade Partners

Renegade Partners is a venture capital firm specifically designed to partner with entrepreneurs who are about to cross a critical inflection point in their business (we call it the supercritical phase) and help these companies become outliers . Everything we do—our team, our processes, and our culture—is in service of achieving this mission. Founded by Renata Quintini and Roseanne Wincek, Renegade manages $100 million. For more information, visit

About XYZ Venture Capital

Operating with the belief that execution solves all problems, XYZ is a venture capital firm that invests in early-stage founders to help them go faster. XYZ aims to help entrepreneurs build sustainable businesses in fintech, corporate and technology sectors like insurance and the public sector. The company primarily supports talented founders in the early stages of building the business – people who have discovered a key idea and have an unfair advantage by “doing the work” or based on their own lived experience. Follow XYZ at